Professional Documents
Culture Documents
Drug Study 2
Drug Study 2
COLLEGE OF NURSING
4th Floor Faber Hall Building, Xavier Ateneo Main Campus
73 Corrales Avenue 9000 Cagayan de Oro City, Philippines
DRUG STUDY
Mechanism of
Action
Ivabradine is a heart rate lowering agent that works through
selective and specific inhibition of the cardiac pacemaker If
current that controls the spontaneous diastolic depolarisation
in the sinus node and regulates heart rate.
Contraindications
Resting heart rate <70 beats/min prior to treatment,
cardiogenic shock, acute MI, severe hypotension (<90/50
mmHg), sick sinus syndrome, SA block, unstable or acute
heart failure, pacemaker dependent, unstable angina, 3rd
degree AV block. Severe hepatic impairment. Pregnancy and
lactation. Concurrent use w/ potent CYP3A4 inhibitors (e.g.
azole antifungals, macrolides, HIV protease inhibitors or
nefazodone), moderate CYP3A4 inhibitors (e.g. verapamil or
diltiazem).
Adverse
Reactions Luminous phenomena in the visual field (phosphenes), blurred
vision, bradycardia, other cardiac arrhythmias, syncope,
hypotension, asthenia, fatigue, headache, dizziness, nausea,
constipation, diarrhoea, dyspnoea, muscle cramps, skin
reactions, angioedema, hyperuricaemia, eosinophilia, elevated
blood-creatinine concentrations.
Side Effects
o Blurred vision.
o chest pain or discomfort.
o fast or irregular heartbeat.
o headache.
o lightheadedness, dizziness, or fainting.
o pounding in the ears.
o slow or irregular heartbeat.
o unusual tiredness.
Nursing
Responsibilities Monitor heart rate prior to initiation of treatment, prior to
increasing dose or after decreasing dose; BP, cardiac rhythm.
DRUG STUDY
Mechanism of
Action Trimetazidine inhibits β-oxidation of fatty acids by blocking
long-chain 3-ketoacyl-CoA thiolase, with the effect of
enhancing glucose oxidation, resulting in more efficient
production of ATP with less oxygen demand. It prevents a
decrease in intracellular ATP levels by preserving energy
metabolism in cells exposed to ischaemia or hypoxia, thus
ensuring the proper functioning of ionic pumps and
transmembrane Na-K flow without changing haemodynamic
parameters.
Contraindications
Parkinson's disease, parkinsonian symptoms, restless leg
syndrome, tremors, and other related movement disorders.
Severe renal impairment (CrCl <30 mL/min). Lactation.
Adverse
Reactions Significant: New-onset or worsening of parkinsonian symptoms
(e.g. akinesia, hypertonia, tremor).
Cardiac disorders: Rarely, palpitations, extrasystoles, tachycardia.
Gastrointestinal disorders: Nausea, vomiting, abdominal pain,
diarrhoea, dyspepsia.
General disorders and administration site conditions: Asthenia.
Nervous system disorders: Headache, dizziness.
Skin and subcutaneous tissue disorders: Rash, urticaria, pruritus.
Vascular disorders: Rarely, arterial hypotension, orthostatic
hypotension, flushing.
Side Effects
Nausea, vomiting.
Abdominal pain, indigestion.
Diarrhoea.
Dizziness.
Headache.
Feeling weak.
Rashes.
DRUG STUDY
Therapeutic: Bronchodilator
Indication
Management of reversible bronchospasm
Nursing
Responsibilities
o Assess vital signs before and after administration
o Assess client history for any contraindications
o Assess for any hypersensitivity to any component of the
drug Assess drugs already being taken for any
adverse drug interactions
o Explain the side effects that may occur and also danger
signs for adverse reactions
o Instruct patients/ SO with the proper use or steps of the
procedure
DRUG STUDY
Mechanism of
Action Thought to produce analgesia and exert its anti-inflammatory
effect by inhibiting prostaglandin and other substances that
sensitize pain receptors. Drug may relieve fever through
central action in the hypothalamic heat-regulating center. In
low doses, drug also appears to interfere with clotting by on
keeping a platelet-aggregating substance so from forming.